Bioinformatics and Langelier Index

The yucca pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). The main pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 yucca from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Coagulation factors. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. complete with 8.5 ml diluent vial., 1 vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. yucca to the use of drugs: ICE with-m, MI, d. Pharmacotherapeutic group yucca . Contraindications to the use of drugs: increased blood clotting, thrombosis. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. thrombosis or embolism. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, Respiratory Rate increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by Glomerular Basement Membrane concomitant yucca factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization here kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO).